Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
BJU International|December 20, 2005
Therapeutic options in androgen-independent prostate cancer: building on docetaxelDaniel PetrylakUrologic Oncology|March 12, 2017
Navigating the evolving therapeutic landscape in advanced prostate cancerE David Crawford, Daniel Petrylak, Oliver SartorClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancerRobert Dreicer, Daniel Petrylak, David Agus, et al.BJU International|September 8, 2007
Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removedPhillip M Pierorazio, James M McKiernan, Tara R McCann, et al.Targeted Oncology|September 20, 2019
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current StatePetros Grivas, Bradley J Monk, Daniel Petrylak, et al.Cancer|September 7, 2002
Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinomaJonathan S Goldberg, Manuel Vargas, Alyssa S Rosmarin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480Eric J Small, Susan Halabi, Mark J Ratain, et al.Cancer|June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 studyDavid J Vaughn, Sandy Srinivas, Walter M Stadler, et al.Journal of the National Cancer Institute|October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapySusan Halabi, Chen-Yen Lin, Eric J Small, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinomaStephen A Boorjian, Matthew I Milowsky, Jodi Kaplan, et al.Pageof 3